<link rel="stylesheet" href="/res/styles.39be4579664c3a48.css">
Artículo

Proliferation index and pseudoprogression as predictors of the therapeutic efficacy of suicide gene therapy for canine melanoma

Fondello, Chiara Icon; Agnetti, Lucrecia Icon; Glikin, Gerardo Claudio Icon; Finocchiaro, Liliana Maria Elena Icon

Otros responsables

Fecha

12/2018

Editorial

Lippincott Williams

Revista

Melanoma Research

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0960-8931

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Resumen

In our veterinary clinical trials, the combination of systemic immunotherapy with local HSVtk/GCV suicide gene (SG) treatment induced tumor pseudo-progression as part of a strong local anti-tumor response. This phenomenon could be due to tumor inflammation, increased vascular permeability and to different tumor growth rates before, during and after SG therapy. The proliferation index (PI: the fraction of viable cells in S, G2/M and hyperdiploid phases) would reflect the in vivo and in vitro proportion of proliferating melanoma cells in the absence of treatment (PIB) or in response to SG (PISG).The extent of in vivo and in vitro melanoma cells response to SG exhibited a reverse correlation with PIB and a direct correlation with PISG. Then, the final SG outcome depended on the balance between PIB-dependent "re-growth resistance" vs. "re-growth sensitivity" to SG treatment (PIGS). In all the cell lines derived from canine tumors presenting partial responses to SG treatment, PISG prevailed over PIB. Conversely, as more aggressive was the tumor (greater PIB of the cell line) more the balance displacement towards re-growth resistance overcome SG re-growth sensitivity. All these parameters could have prognostic value for SG treatment response and allow us to glimpse the clinical benefit of this therapy.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa